

AMENDMENTS TO THE CLAIMS:

Please amend claim 1, add claims 6-10, and cancel claim 2 without prejudice or disclaimer as follows. This listing of claims replaces all prior versions, and listings of claims in the application.

LISTING OF CLAIMS:

1. (Currently Amended) A method for the treatment of glycine-extended gastrin-17 dependent gastrointestinal tumors, whose growth is stimulated by glycine-extended gastrin-17, comprising: administering to a mammal a therapeutically effective amount of an anti-G17 immunogenic composition, wherein the amount of the immunogenic composition administered is sufficient to inhibit physiological effects of gastrin-17, amidated gastrin and glycine-extended gastrin-17.
2. Cancelled.
3. (Previously Presented) The method of claim 1, wherein the gastrointestinal tumors contain gastrin/cholecystokinin B (CCK-B) receptors.
4. (Original) The method of claim 1, wherein the gastrointestinal tumors are colorectal adenocarcinomas.
5. (Original) The method of claim 1, wherein the mammal is a human.
6. (New) The method of claim 1, further comprising:
assaying a serum sample from the mammal to determine the level of extended gastrin 17 to determine a dosage of the composition for neutralization of gastrin-17 and glycine-extended gastrin-17 to inhibit growth of tumor cells.
7. (New) The method of claim 1, further comprising:
monitoring antibody titer levels against glycine-extended glycine-17 and amidated glycine-17; and
administering booster immunizations of the immunogenic composition to maintain an antibody titer effective to neutralize glycine-extended glycine-17 and amidated glycine-17.
8. (New) A method for the treatment of gastrointestinal tumors, whose growth is stimulated by glycine-extended gastrin-17, comprising: administering to a mammal a therapeutically effective amount antibodies against gastrin-17, wherein the amount of antibodies administered is sufficient to inhibit physiological effects of gastrin-17, amidated gastrin and glycine-extended gastrin-17 to effect treatment of the tumor.

9. (New) The method of claim 8, wherein the antibodies are monoclonal antibodies.
- 10 (New) The method of claim 9, wherein the antibodies are human, humanized or chimeric.